Larimar Therapeutics (LRMR) Income from Continuing Operations (2016 - 2020)
Historic Income from Continuing Operations for Larimar Therapeutics (LRMR) over the last 7 years, with Q1 2020 value amounting to -$3.6 million.
- Larimar Therapeutics' Income from Continuing Operations rose 7254.66% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 3849.55%. This contributed to the annual value of -$45.4 million for FY2019, which is 2568.26% up from last year.
- Larimar Therapeutics' Income from Continuing Operations amounted to -$3.6 million in Q1 2020, which was up 7254.66% from -$7.3 million recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' Income from Continuing Operations ranged from a high of -$3.6 million in Q1 2020 and a low of -$17.8 million during Q1 2016
- For the 5-year period, Larimar Therapeutics' Income from Continuing Operations averaged around -$13.0 million, with its median value being -$13.1 million (2019).
- Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 3275.68% in 2016, then skyrocketed by 7254.66% in 2020.
- Over the past 5 years, Larimar Therapeutics' Income from Continuing Operations (Quarter) stood at -$10.3 million in 2016, then decreased by 26.76% to -$13.1 million in 2017, then fell by 10.72% to -$14.5 million in 2018, then surged by 49.65% to -$7.3 million in 2019, then skyrocketed by 50.66% to -$3.6 million in 2020.
- Its Income from Continuing Operations was -$3.6 million in Q1 2020, compared to -$7.3 million in Q4 2019 and -$12.9 million in Q3 2019.